Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 16, 2023

BUY
$0.35 - $0.72 $7,739 - $15,921
22,113 Added 131.29%
38,956 $14,000
Q4 2022

Feb 14, 2023

BUY
$0.32 - $8.27 $5,389 - $139,291
16,843 New
16,843 $6,000
Q2 2022

Aug 15, 2022

BUY
$0.58 - $1.13 $68,867 - $134,172
118,737 Added 748.19%
134,607 $79,000
Q1 2022

May 16, 2022

SELL
$0.73 - $1.81 $43,042 - $106,721
-58,962 Reduced 78.79%
15,870 $16,000
Q4 2021

Feb 14, 2022

SELL
$1.66 - $2.64 $25,954 - $41,276
-15,635 Reduced 17.28%
74,832 $124,000
Q3 2021

Nov 15, 2021

SELL
$2.58 - $3.36 $143,675 - $187,111
-55,688 Reduced 38.1%
90,467 $243,000
Q2 2021

Aug 11, 2021

BUY
$2.7 - $3.81 $185,139 - $261,251
68,570 Added 88.38%
146,155 $486,000
Q1 2021

May 17, 2021

BUY
$3.02 - $5.16 $146,273 - $249,924
48,435 Added 166.16%
77,585 $258,000
Q4 2020

Feb 16, 2021

SELL
$2.66 - $4.18 $273,307 - $429,482
-102,747 Reduced 77.9%
29,150 $110,000
Q3 2020

Nov 16, 2020

BUY
$3.01 - $3.88 $205,197 - $264,507
68,172 Added 106.98%
131,897 $415,000
Q2 2020

Aug 14, 2020

BUY
$2.33 - $4.6 $51,385 - $101,448
22,054 Added 52.92%
63,725 $203,000
Q1 2020

May 15, 2020

BUY
$1.91 - $4.52 $55,957 - $132,422
29,297 Added 236.76%
41,671 $112,000
Q3 2019

Nov 14, 2019

BUY
$2.74 - $4.65 $4,658 - $7,905
1,700 Added 15.93%
12,374 $40,000
Q2 2019

Aug 16, 2019

BUY
$2.66 - $6.28 $28,392 - $67,032
10,674 New
10,674 $39,000
Q2 2018

Aug 14, 2018

SELL
$6.68 - $11.0 $526,778 - $867,449
-78,859 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$10.14 - $12.38 $799,630 - $976,274
78,859 New
78,859 $863,000

Others Institutions Holding MBIO

About MUSTANG BIO, INC.


  • Ticker MBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,222,000
  • Market Cap $27.4M
  • Description
  • Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (...
More about MBIO
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.